Liver Cirrhosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cirrhosis is a condition that arises when the liver undergoes fibrosis and the formation of nodules, leading to a prolonged injury that disrupts its typical lobular structure. Chronic liver conditions often evolve into cirrhosis. In developed nations, prevalent causes include hepatitis C virus (HCV), alcoholic liver disease, and non-alcoholic steatohepatitis (NASH), whereas in developing regions, hepatitis B virus (HBV) and HCV are more common culprits. Although the global prevalence of cirrhosis remains uncertain, estimates suggest it ranges from 0.15% to 0.27% in the United States. Various cells contribute to cirrhosis, including hepatocytes and sinusoidal lining cells like hepatic stellate cells (HSCs), sinusoidal endothelial cells (SECs), and Kupffer cells (KCs). HSCs, found within liver sinusoids, primarily store vitamin A. Multiple imaging techniques complement laboratory tests to aid cirrhosis diagnosis, such as ultrasound, CT scans, MRI, and transient elastography (fibroscan). Liver damage is irreversible, emphasizing the importance of preventing further injury to halt disease progression. General management strategies to prevent chronic liver disease encompass alcohol avoidance, HBV and HCV vaccination, balanced nutrition, weight management, and prompt treatment of precipitating factors like dehydration, hypotension, and infections. This necessitates routine monitoring of volume status, kidney function, varices development, and the potential progression to hepatocellular carcinoma (HCC).
Thelansis’s “Liver Cirrhosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Liver Cirrhosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Liver Cirrhosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Liver Cirrhosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment